EGFR and non-small cell lung carcinoma: Osimertinib molecular structure allows the inhibitor to covalently bind to T790M-mutated EGFR with much higher affinity than with wild-type EGFR, guaranteeing a treatment with milder side effects and more durable responses for NSCLC patients.